Stockscreener 앱 받기
84.54
1.50%
1.25
시간 외 거래:
84.54
전일 마감가:
$83.29
열려 있는:
$83.88
하루 거래량:
413.64K
Relative Volume:
0.46
시가총액:
$6.37B
수익:
-
순이익/손실:
$-255.84M
주가수익비율:
-20.06
EPS:
-4.2149
순현금흐름:
$-232.60M
1주 성능:
+3.06%
1개월 성능:
+0.63%
6개월 성능:
+53.72%
1년 성능:
+137.67%
1일 변동 폭
$83.39
$85.03
1주일 범위
$80.52
$85.45
52주 변동 폭
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
84.54 | 6.28B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Hold |
| 2026-01-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | 개시 | Wolfe Research | Peer Perform |
| 2025-12-17 | 개시 | Stephens | Overweight |
| 2025-12-10 | 개시 | Deutsche Bank | Buy |
| 2025-11-03 | 개시 | Craig Hallum | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-07 | 재확인 | BTIG Research | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Insider to sell 22,000 shares at APGE (NASDAQ: APGE) after 11,000 sold - Stock Titan
CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn - MarketBeat
Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation - MSN
Insider sales reported for APGE (NASDAQ: APGE) — five 2,000-share trades - Stock Titan
Rothschild & Co Redburn Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $140 - Moomoo
Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Rothschild Redburn initiates Apogee stock with buy on AD therapy - Investing.com UK
Rothschild Redburn initiates Apogee stock with buy on AD therapy By Investing.com - Investing.com India
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Apogee Therapeutics (APGE) Study result Summary - Quartr
Apogee Therapeutics (APGE) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Apogee Therapeutics Stock Surges as Investors Bet on Immunology Breakthrough - HarianBasis.co
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters - Yahoo Finance
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily
Apogee Therapeutics, Inc. ($APGE) CEO 2025 Pay Revealed - Quiver Quantitative
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift - TipRanks
Apogee Therapeutics (APGE) 2026 meeting to vote on directors, pay and auditor - Stock Titan
Two directors resign from Apogee Therapeutics (NASDAQ: APGE) board, shrinking it to seven - Stock Titan
Certain Common Stock of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Pre-Funded Warrants of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Stock Options of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Apogee Thera (APGE) Stock Price Target | Q4 2025: Earnings Beat EstimatesTrending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
APGE (Apogee Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares rise modestly after its latest quarterly earnings release.GDR - Cổng thông tin điện tử tỉnh Tây Ninh
APGE (Apogee Therapeutics Inc.) Q4 2025 EPS outpaces forecasts, shares gain as investors reward narrower than expected loss.Social Flow Trades - UBND thành phố Hải Phòng
APGE Earnings History & Surprises | EPS & Revenue Results | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Apogee Therapeutics (APGE) CEO exercises options, holds 1.14M shares - Stock Titan
Apogee Therapeutics stock hits all-time high at 92.48 USD By Investing.com - Investing.com India
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CFO Henderson sells $180,000 in stock - Investing.com
Apogee Therapeutics CFO Henderson sells $180,000 in stock By Investing.com - Investing.com India
Apogee Therapeutics (APGE) CFO sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics stock hits all-time high at 92.48 USD - Investing.com
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):